Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Merck Revises Guidance To Include $700 Million Less In Vytorin/Zetia Sales

This article was originally published in The Pink Sheet Daily

Executive Summary

Company, however, reaffirms EPS guidance for the year.

You may also be interested in...



Lipitor Study Creates More Doubts On CRP Study Used To Expand Crestor Label

A new analysis of a large European trial presented at the American Heart Association annual meeting has further damaged the case for using C-reactive protein levels as a guide for statin therapy.

Lipitor Study Creates More Doubts On CRP Study Used To Expand Crestor Label

A new analysis of a large European trial presented at the American Heart Association annual meeting has further damaged the case for using C-reactive protein levels as a guide for statin therapy.

Merck Outlines Plans For 2009 NDA Filings; Migraine Drug Is Best Bet

Merck's fledgling bioventures business may have dominated headlines following the company's recent analyst day, but the firm's other initiatives are likely to contribute more to near-term growth as Merck tries to address the revenue gap that will be left by key patent expirations in the next few years

Related Content

Topics

Latest News
See All
UsernamePublicRestriction

Register

PS067624

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel